ES2637150T3 - Cristal de derivado de dispiropirrolidina - Google Patents

Cristal de derivado de dispiropirrolidina Download PDF

Info

Publication number
ES2637150T3
ES2637150T3 ES13835941.9T ES13835941T ES2637150T3 ES 2637150 T3 ES2637150 T3 ES 2637150T3 ES 13835941 T ES13835941 T ES 13835941T ES 2637150 T3 ES2637150 T3 ES 2637150T3
Authority
ES
Spain
Prior art keywords
weight
crystal
present
mdm2
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13835941.9T
Other languages
English (en)
Spanish (es)
Inventor
Shoko Yoshida
Yuuichi Sugimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Application granted granted Critical
Publication of ES2637150T3 publication Critical patent/ES2637150T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES13835941.9T 2012-09-06 2013-09-05 Cristal de derivado de dispiropirrolidina Active ES2637150T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012195761 2012-09-06
JP2012195761 2012-09-06
PCT/JP2013/073865 WO2014038606A1 (ja) 2012-09-06 2013-09-05 ジスピロピロリジン誘導体の結晶

Publications (1)

Publication Number Publication Date
ES2637150T3 true ES2637150T3 (es) 2017-10-11

Family

ID=50237214

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13835941.9T Active ES2637150T3 (es) 2012-09-06 2013-09-05 Cristal de derivado de dispiropirrolidina

Country Status (12)

Country Link
US (8) US9359368B2 (cg-RX-API-DMAC7.html)
EP (1) EP2894156B1 (cg-RX-API-DMAC7.html)
JP (1) JP6016284B2 (cg-RX-API-DMAC7.html)
KR (1) KR102217410B1 (cg-RX-API-DMAC7.html)
CN (1) CN104812757B (cg-RX-API-DMAC7.html)
BR (1) BR112015004816B1 (cg-RX-API-DMAC7.html)
CA (1) CA2884238C (cg-RX-API-DMAC7.html)
ES (1) ES2637150T3 (cg-RX-API-DMAC7.html)
IN (1) IN2015MN00464A (cg-RX-API-DMAC7.html)
RU (1) RU2647840C2 (cg-RX-API-DMAC7.html)
TW (1) TWI586668B (cg-RX-API-DMAC7.html)
WO (1) WO2014038606A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
AU2016209349B2 (en) 2015-01-20 2020-05-07 Arvinas, Inc. Compounds and methods for the targeted degradation of the Androgen Receptor
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
KR102595395B1 (ko) 2015-02-20 2023-10-27 다이이찌 산쿄 가부시키가이샤 암의 병용 치료법
EP3284466A4 (en) * 2015-04-13 2018-12-05 Daiichi Sankyo Company, Limited Treatment method combining mdm2 inhibitor and btk inhibitor
US20180147202A1 (en) 2015-06-05 2018-05-31 Arvinas, Inc. TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
EP3364972A1 (en) * 2015-10-23 2018-08-29 Daiichi Sankyo Company, Limited Dosage regimen of mdm2 inhibitor for treating cancers
CN108135884A (zh) * 2015-10-23 2018-06-08 第三共株式会社 用于治疗aml的药物组合物和治疗有此需要的对象中的aml的方法
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
IL290809B2 (en) 2016-11-01 2024-01-01 Arvinas Operations Inc Tau-protein targeting protacs and associated methods of use
WO2018102725A1 (en) 2016-12-01 2018-06-07 Arvinas, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
WO2018118598A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
WO2018119448A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
CA3047586A1 (en) 2016-12-23 2018-06-28 Arvinas Operations, Inc. Egfr proteolysis targeting chimeric molecules and associated methods of use
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
EP3573977A4 (en) 2017-01-26 2020-12-23 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
EP3841100A1 (en) 2018-08-20 2021-06-30 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
AU2020336309A1 (en) 2019-08-26 2022-03-17 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
JP2023539663A (ja) 2020-08-28 2023-09-15 アルビナス・オペレーションズ・インコーポレイテッド 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
TW202214236A (zh) 2020-09-14 2022-04-16 美商亞文納營運公司 用於靶向降解雌激素受體之化合物之結晶及非晶形形式
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
EP4584258A1 (en) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
KR20250151412A (ko) 2023-01-26 2025-10-21 아비나스 오퍼레이션스, 인코포레이티드 세레블론계 kras 분해 단백질 및 이와 관련된 용도
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6740495B1 (en) 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
US6979551B2 (en) 2000-04-03 2005-12-27 Rigel Pharmaceuticals, Inc. Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
JP4361798B2 (ja) 2001-12-18 2009-11-11 エフ．ホフマン−ラ ロシュ アーゲー Ｍｄｍ２インヒビターとしてのシス−イミダゾリン
CA2469187C (en) 2001-12-18 2012-07-17 F. Hoffmann-La Roche Ag Cis-2,4,5-triphenyl-imidazolines and their use in the treatment of tumors
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
CN1953965B (zh) 2004-05-18 2012-07-04 霍夫曼-拉罗奇有限公司 新型顺式咪唑啉类化合物
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
EA014445B1 (ru) * 2005-02-22 2010-12-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Низкомолекулярные ингибиторы mdm2 и их применения
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
AR059265A1 (es) * 2006-02-07 2008-03-19 Astrazeneca Ab Compuestos espiro condensados con actividad inhibitoria en el receptor vaniloide1 (vr1)
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
CA2644758A1 (en) 2006-03-13 2007-09-20 F. Hoffmann-La Roche Ag Spiroindolinone derivatives
ZA200901224B (en) 2006-08-30 2010-05-26 Univ Michigan New small molecule inhibitors of MDM2 the uses thereof
JP2010504298A (ja) 2006-09-21 2010-02-12 エフ．ホフマン−ラ ロシュ アーゲー オキシンドール誘導体
US7638548B2 (en) 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
BRPI0810082A2 (pt) 2007-03-29 2014-10-21 Novartis Ag 3-imidazolil-indóis para o tratamento de doenças proliferativas
US7553833B2 (en) 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
US7834179B2 (en) 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8134001B2 (en) 2007-12-14 2012-03-13 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
US7723372B2 (en) 2008-03-19 2010-05-25 Hoffman-La Roche Inc. Spiroindolinone derivatives
AR073578A1 (es) 2008-09-15 2010-11-17 Priaxon Ag Pirrolidin-2-onas
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
RS52660B (sr) 2008-09-18 2013-06-28 F. Hoffmann-La Roche Ag Supstituisani pirolidin-2-karboksamidi
JP5520236B2 (ja) 2009-01-16 2014-06-11 第一三共株式会社 プロリン環構造を有するイミダゾチアゾール誘導体
US20100190814A1 (en) 2009-01-26 2010-07-29 Li Chen Spiroindolinone derivative prodrugs
US7928233B2 (en) 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8217051B2 (en) 2009-02-17 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8076482B2 (en) * 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
US8017607B2 (en) 2009-10-14 2011-09-13 Hoffmann-La Roche Inc. N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions
UA107814C2 (uk) 2009-11-12 2015-02-25 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Спірооксіндольні антагоністи мdм2
US20110118283A1 (en) 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
KR20130050938A (ko) 2010-04-09 2013-05-16 더 리젠츠 오브 더 유니버시티 오브 미시건 질환 치료시 사용하기 위한 ｍｄｍ2 억제제에 대한 바이오마커
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
US20120010235A1 (en) 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
US20120046306A1 (en) 2010-08-18 2012-02-23 David Joseph Bartkovitz Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
US20130200039A1 (en) 2010-09-08 2013-08-08 Basf Se Aqueous polishing compositions containing n-substituted diazenium dioxides and/or n'-hydroxy-diazenium oxide salts
US20120065210A1 (en) 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
US20120071499A1 (en) 2010-09-20 2012-03-22 Xin-Jie Chu Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
WO2012076513A1 (en) 2010-12-09 2012-06-14 F. Hoffmann-La Roche Ag 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer
MY172862A (en) * 2011-03-10 2019-12-13 Daiichi Sankyo Co Ltd Dispiropyrrolidine derivatives
CN103717605B (zh) * 2011-05-11 2016-05-18 密执安州立大学董事会 螺-羟吲哚mdm2拮抗剂
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶

Also Published As

Publication number Publication date
CN104812757A (zh) 2015-07-29
US9359368B2 (en) 2016-06-07
US20180155355A1 (en) 2018-06-07
RU2647840C2 (ru) 2018-03-21
EP2894156A1 (en) 2015-07-15
US20150210707A1 (en) 2015-07-30
US9884871B2 (en) 2018-02-06
KR102217410B1 (ko) 2021-02-18
KR20150048140A (ko) 2015-05-06
US20170081335A1 (en) 2017-03-23
HK1210172A1 (en) 2016-04-15
US20160244458A1 (en) 2016-08-25
US9540386B2 (en) 2017-01-10
CA2884238C (en) 2017-10-03
EP2894156B1 (en) 2017-05-17
US20170081336A1 (en) 2017-03-23
BR112015004816B1 (pt) 2022-04-26
CA2884238A1 (en) 2014-03-13
US10030030B2 (en) 2018-07-24
JP6016284B2 (ja) 2016-10-26
TW201410681A (zh) 2014-03-16
US10023578B2 (en) 2018-07-17
US20170081337A1 (en) 2017-03-23
WO2014038606A1 (ja) 2014-03-13
IN2015MN00464A (cg-RX-API-DMAC7.html) 2015-09-04
RU2015112098A (ru) 2016-10-27
BR112015004816A2 (pt) 2017-07-04
CN104812757B (zh) 2016-11-09
US9718831B2 (en) 2017-08-01
US9745315B2 (en) 2017-08-29
JPWO2014038606A1 (ja) 2016-08-12
TWI586668B (zh) 2017-06-11
EP2894156A4 (en) 2016-03-23
US9718830B2 (en) 2017-08-01
US20170081334A1 (en) 2017-03-23
US20180155356A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
ES2637150T3 (es) Cristal de derivado de dispiropirrolidina
JP7383652B2 (ja) Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
ES3034158T3 (en) Novel salt of terphenyl compound
ES3044433T3 (en) Compositions for use in a method of treating an estrogen receptor associated cancer
ES2402524T5 (es) Sal de malato de la N-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-N'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida y formas cristalinas de la misma para el tratamiento del cáncer
RU2728827C2 (ru) Кристаллическая форма ингибитора тирозинкиназы брутона и способ её получения
CN116096372B (zh) 一种egfr抑制剂、其制备方法和在药学上的应用
TW202311259A (zh) 化合物i的新形式及其應用
ES3027566T3 (en) Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
JP6880023B2 (ja) 改善された特性を有するβ−グアニジノプロピオン酸の薬学的に許容される塩及びその使用
WO2021098859A1 (zh) 氮杂七元环类抑制剂及其制备方法和应用
JP2018531280A6 (ja) 改善された特性を有するβ−グアニジノプロピオン酸の薬学的に許容される塩及びその使用
WO2022223020A1 (zh) 靶向活化与失活态kras g12d的抑制剂
BR112021005171A2 (pt) derivados de quinuclidina-3-ona e seu uso em tratamento de câncer
TWI752026B (zh) 一類蛋白激酶抑制劑
JP2020536113A (ja) 上皮成長因子受容体阻害剤
US9884856B2 (en) Crystal form of Dabrafenib mesylate and preparation method thereof
WO2020103939A1 (zh) 三唑并环类化合物、其制备方法、中间体和应用
ES2784325T3 (es) Formas cristalinas de sales farmacéuticamente aceptables de N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina y usos de las mismas
CN111205244B (zh) 噻唑并环类化合物、其制备方法、中间体和应用
CN109111439B (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
EP4512808A1 (en) Crystal of 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative
KR20250154490A (ko) 방향족 아미드 유도체, 이의 제조 방법, 및 그의 용도
EP4393908A1 (en) Bis-pyrazolyl-methane compounds affecting kras
JP2021521282A (ja) Ｃｄｋ４／６阻害剤、その薬学的に許容可能な塩と結晶多形体、及びその応用